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Abstract
A fixed-dose combination of artemether-lumefantrine (AL, Coartem®) has shown high efficacy, good tolerability
and cost-effectiveness in adults and children with uncomplicated malaria caused by Plasmodium falciparum.
Lumefantrine bioavailability is enhanced by food, particularly fat.
As the fat content of sub-Saharan African meals is approximately a third that of Western countries, it raises the
question of whether fat consumption by African patients is sufficient for good efficacy. Data from healthy
volunteers have indicated that drinking 36 mL soya milk (containing only 1.2 g of fat) results in 90% of the
lumefantrine absorption obtained with 500 mL milk (16 g fat). African diets are typically based on a carbohydrate
staple (starchy root vegetables, fruit [plantain] or cereals) supplemented by soups, relishes and sauces derived
from vegetables, pulses, nuts or fish. The most important sources of dietary fat in African countries are oil crops
(e.g. peanuts, soya beans) and cooking oils as red palm, peanut, coconut and sesame oils. Total fat intake in the
majority of subSaharan countries is estimated to be in the range 30–60 g/person/day across the whole population
(average 43 g/person/day). Breast-feeding of infants up to two years of age is standard, with one study estimating
a fat intake of 15–30 g fat/day from breast milk up to the age of 18 months. Weaning foods typically contain low
levels of fat, and the transition from breast milk to complete weaning is associated with a marked reduction in
dietary fat. Nevertheless, fat intake >10 g/day has been reported in young children post-weaning. A randomized
trial in Uganda reported no difference in the efficacy of AL between patients receiving supervised meals with a
fixed fat content (~23 g fat) or taking AL unsupervised, suggesting that fat intake at home was sufficient for optimal
efficacy. Moreover, randomized trials in African children aged 5–59 months have shown similar high cure rates to
those observed in older populations, indicating that food consumption is adequate post-weaning. In conclusion, it
appears that only a very small amount of dietary fat is necessary to ensure optimal efficacy with AL and that the
fat content of standard meals or breast milk in sub-Saharan Africa is adequate.
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Progress in the ontrol and treatment of malaria in Africa
has been threatened by growing resistance to previously
effective therapies, notably chloroquine and sulphadox-
ine/pyrimethamine. Combination therapy is now widely
regarded as the most effective strategy for limiting the
emergence and spread of resistance and combination
treatment based on artemisinin is now recommended by
the World Health Organization (WHO) [1].
Artemether-lumefantrine (AL, Coartem®, Novartis
Pharma AG, Basel, Switzerland) combines the artemisi-
nin-derivative artemether, which has a prompt onset of
action and provides fast symptomatic relief, with lume-
fantrine, which has a slower onset of action and clears
residual parasites [2]. AL has consistently shown high effi-
cacy and tolerability in African adults and children with
uncomplicated malaria caused by Plasmodium falciparum,
achieving 28-day polymerase chain reaction (PCR)-cor-
rected parasitological cure rates of >95% [3-7]. AL is the
first and only fixed-dose artemisinin-based combination
treatment (ACT) pre-qualified by the WHO, and has now
been adopted as first-line treatment for uncomplicated
malaria due to P falciparum in more than 20 African coun-
tries including Kenya, Malawi, Uganda, Tanzania,
Mozambique, Nigeria, South Africa and Ethiopia. Many
other countries have also switched to AL as first-line ther-
apy. The manufacturer introduced price reductions in
2006 and 2008, cutting the public sector price by approx-
imately 50% since 2001.
Cost-effectiveness assessments, one based on data from a
randomized trial in Tanzania [8] and another based on
public health data collected in the field in Zambia [9],
have confirmed that AL offers a cost-effective treatment
option compared to other antimalarial drugs.
Artemether and lumefantrine are lipophilic molecules.
Food, especially dietary fat, enhances the bioavailability
of both agents, but the effect is more pronounced with
lumefantrine [2]. The fat content of African meals tends to
be relatively low; indeed, total fat consumption in sub-
Saharan Africa is approximately a third that of Western
countries [10]. This raises the important question of
whether adults or children prescribed AL in sub-Saharan
Africa consume sufficient fat to ensure parasite clearance.
This article reviews the typical components and fat con-
tent of African diets and consider the adequacy of fat
intake in terms of achieving optimal efficacy.
Characteristics of lumefantrine absorption
Lumefantrine, like several other lipophilic antimalarial
agents, is absorbed slowly after oral administration, and
bioavailability varies between individuals [2,11-13]. Con-
comitant food increases lumefantrine bioavailability [14].
In a double-blind trial of 260 patients with uncompli-
cated malaria in Thailand, Ezzet et al showed that both the
extent and variability of lumefantrine absorption
improved with clinical recovery as normal food intake
was resumed [14]. Oral bioavailability increased by 108%
when a normal meal was eaten close to AL dosing, com-
pared to the fasting condition. Adequate lumefantrine
absorption is important in order to avoid low plasma con-
centrations with risk of treatment failure [2].
The key question for the healthcare team is how much die-
tary fat is necessary to achieve complete parasite clearance
with AL. This question has been investigated by Ashley et
al in a cross-over pharmacokinetic study in which lume-
fantrine exposure (area under the curve, AUC) was meas-
ured in healthy volunteers after a single dose of AL was
administered with different volumes of soya milk or with
no milk [15]. Based on these data, the authors constructed
a population model which indicated that in this popula-
tion of healthy volunteers, drinking 36 mL of soya milk
(containing only 1.2 g of fat) resulted in 90% of the lume-
fantrine exposure obtained with 500 mL milk (16 g fat);
74 ml of soya milk (2.4 g of fat) achieved 99% of the expo-
sure seen with 500 mL (Figure 1). Ashley and colleagues
pointed out that 1.2 g of fat can be obtained in a remark-
ably small amount of food: for example, a single teaspoon
of vegetable oil contains 5 g of fat.
Typical components of African diets
Diets in Africa vary widely according to regional, eco-
nomic, environmental and cultural factors. Nevertheless,
there are certain typical patterns of food consumption
(Table 1). African diets are traditionally based on a carbo-
hydrate staple that is supplemented by soups, relishes and
sauces derived from a wide range of other foodstuffs. The
carbohydrate component may be primarily cereals (e.g.
maize, sorghum, millet, rice), starchy roots (e.g. potatoes,
sweet potatoes, yams, cassava) or fruit (plantain), depend-
ing on the country and local area. In recent years there has
been a trend away from the consumption of roots towards
maize, rice and wheat, particularly in cities [16]. Accom-
paniments to the carbohydrate staple are usually com-
posed of vegetables (e.g. eggplant, cabbage, carrots,
spinach, kales, French beans, onions), pulses, nuts (partic-
ularly peanuts), meat (chicken, beef or pork) or fish,
depending on local availability, household income, sea-
son and community habits, with the greatest variety seen
in coastal regions and the fertile highlands [16].
The Food and Agriculture Organization (FAO) of the
United Nations compiles data on various aspects of food
production and availability [17]. These statistics offer a
valuable source of information, although it should be
borne in mind that estimates are based on the amount of
food available for human consumption, rather thanPage 2 of 7
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Table 2 summarizes the consumption of selected food
groups in sub-Saharan countries based on FAO data, and
highlight the predominance of cereals and starchy root
vegetables [18].
The most important sources of dietary fat in African coun-
tries are oil crops (e.g. peanuts, soy beans) and oils
obtained from vegetables or plants such as red palm oil,
groundnut oil, coconut oil and sesame oil. These are
widely used in food preparation, for frying or as additions
to sauces and stews. Additional contributions to fat intake
are made by other commonly-used foodstuffs such as nuts
and pulses. Table 3 describes the typical fat content of
some staple foodstuffs [19]. While food composition
inevitably varies according to crop variety, growing condi-
tions and freshness, these illustrate that relatively small
amounts of certain widely-consumed items such as soya
beans and ground nuts contain high levels of fat. A further
contribution comes from whole-grain cereals if the cereal
germ is not separated out prior to milling: for example,
maize contains 4.8 g/100 g [19] and is a staple food in
many countries.
Total fat intake in African countries
Total energy intake per person across sub-Saharan Africa is
currently estimated to be 2220 kcal/day, compared to
3340 kcal/day in developed countries [10]. Regional dif-
ferences exist, most notably a higher average energy intake
in West Africa compared to other areas (Table 4). Esti-
mates of total fat intake from the FAO for the period
2001–2003 suggest that the average total amount of fat
consumed per person per day vary considerably between
subSaharan African countries (Table 5) [10]. The majority
of countries, however, fall into the range 30–60 g/person/
day. The daily intake of fat across subSaharan Africa is esti-
mated to be 43 g/person/day, with the highest fat intake
in West Africa (Table 1); for comparison, people in devel-
oped countries consume 123 g/person/day, on average
[10]. The per capita daily intake of fat has generally
remained stable or shown an upward trend in the major-
ity of African countries over the last three decades [10],
with exceptions being due to major conflicts or famines.
Fat content of breast milk and weaning foods
It is standard to breast-feed infants up to 4–6 months in
all regions of Africa, although supplementary cow's milk
may be given. The fat content of breast milk in rural Afri-
can areas varies with the season, stage of lactation and
between individual mothers, but an investigation in a
farming community in The Gambia recorded an average
fat content of 40 g/L breast milk [20], similar to that
reported in other parts of the world [21-23]. Breast-fed
infants in The Gambia have been shown to receive 15–30
g fat/day from breast milk up to the age of 18 months,
with breast milk continuing to make a major contribution
Relationship between volume of soya milk consumed and estimated lum fantri e absorption (AUC) in healthy volun-teersFigure 1
Relationship between volume of soya milk consumed and 
estimated lumefantrine absorption (AUC) in healthy volun-
teers. (Reprinted with permission http://www.blackwellsyn-
ergy.com) [15].
Table 1: Typical components of regional African diets for adults and infants
Region Adults Infants
East Africa Starchy foods (e.g. cooked bananas, potatoes, cassava, corn, wheat 
products, rice). Food consumed to accompany starches includes beef, 
lamb, poultry, stews made of legumes, soups, vegetables (mostly fried in 
cooking oil or fat or cream) and peanut/groundnut-based sauces
Exclusively 4–6 months unless contraindicated. 
Weaning may start from month 3 onwards
Supplementary milk from cows
Early food: porridge containing milk or coconut oil.
West Africa Bean balls fried with oil, maize fortified with palm oil, groundnuts, bread, 
eggs, rice, yam, beef or fish stew, yams, vegetables 
(mostly fried in cooking oil)
Exclusively breast-fed up to 4 to 6 months unless 
contraindicated
Supplementary milk (cow milk or baby formula)
Early foods include chocolate drinks, mashed yam, 
beans
Central Africa Rice, cassava, sorghum, millet, vegetables (fried in peanut oil), palm oil, 
fish, meat
Exclusively breast-fed up to 6 months
Supplementary milk from cows
Early food: porridge from maize meal and milk
Southern Africa Maize, mashed potatoes, vegetables, beef, rice, bread, cassava Exclusively breast-fed up to 6 months unless 
contraindicated
Supplementary milk from cows
Early food: porridge maize mealPage 3 of 7
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infants in The Gambia and the United Kingdom, Prentice
et al found that fat intake from breast milk was at least as
high in the Gambian children while being breast-fed
exclusively [24].
Infants usually continue to receive breast milk until two
years of age, with some food introduced from three
months or later. The first weaning food is usually porridge
made from a cereal such as rice, corn or millet mixed with
water, or possibly cow's milk, with salt and sugar. Such
porridges have a relatively low fat content (e.g. 0.1–0.3 g/
100 g); although addition of soya milk or peanuts in some
regions increases the fat content (1.2–1.9 g/100 g) [25]. In
West Africa there tends to be a greater diversity of early












Burkina Faso 601 6 14 30 56 42 14 16 15 13 47
Burundi 84 5 284 10 13 2 103 632 8 2 93
Cameroon 288 38 213 41 40 19 39 400 28 21 217
Congo, Dem 
Republic of
102 16 82 13 4 12 10 842 8 15 25
Côte 
d'Ivoire
331 40 201 31 21 20 1 619 30 37 103
Ethiopia 384 1 28 23 61 2 35 168 12 4 31
Ghana 249 80 319 27 21 35 2 1107 19 16 88
Kenya 337 12 154 40 263 4 42 164 55 20 102
Malawi 403 10 107 14 12 13 34 504 31 9 54
Mali 502 21 8 51 126 5 25 30 30 18 66
Mozambique 289 6 48 15 12 5 26 665 31 19 17
Nigeria 399 20 185 23 20 21 26 593 31 38 167
Sudan 370 5 83 59 410 11 22 13 55 21 135




307 19 81 27 70 13 28 518 21 14 76
Zimbabwe 355 4 32 42 54 17 13 43 97 26 30
* Excluding products
Table 3: Fat content of typical foodstuffs [19]
Type Food Fat content (g/100 g)
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beans (Table 1).
The transition from breast milk to weaning foods and
then to adult foods is associated with a marked reduction
in the proportion of energy that is obtained from fat. A
study in Kenya was undertaken in infants during the sec-
ond year of life (mean 14–20 months) to assess fat intake
over the period of weaning [26]. In these young children,
the mean quantity of breast milk ingested was calculated
to be 502 ± 239 g per 24 hours, although this varied
widely between individuals [26]. The authors calculated
the average fat intake from milk to be approximately 17 g/
day, which was supplemented by 10.5 g/day from wean-
ing foods. In the period prior to weaning, fat intake from
breast milk decreased to approximately 11 g/day but after
complete weaning the increased food consumption pro-
vided only an additional 3.5 g/day. A further detailed
study in The Gambia has shown that total fat intake
remained relatively stable over the first 17 months of life,
but as the percentage of other foods (notably cereals and
peanuts) increased in the diet, the percentage of energy
from fat decreased from 50% during breast-feeding to
30% during mixed feeding and to 15% after total weaning
[24]. Nevertheless, total fat intake, which was ~25 g/day
until complete weaning, was >10 g/day subsequently.
Cow's milk is only given to infants infrequently in many
African countries because of the low milk yield per animal
and scarcity of preservation equipment, although it is
more common in some countries (e.g. Kenya, Somalia
and Sudan). Where cow's milk is used, however, it is a
good source of fat with a fat content of 30 g/L [19], only
slightly lower than breast milk.
Relevant experience from clinical trials
In most trials of AL in African populations, AL has been
administered under supervision with food or drink given
in the hospital or clinic [4,7,27-29]. Two studies, how-
ever, have assessed 'real-life effectiveness' of AL, in which
the drug was taken unsupervised at home [6,30]. These
are helpful in providing an indication of whether normal,
unsupervised food consumption during AL administra-
tion ensures good efficacy. Piola et al undertook a rand-
omized trial in 957 patients in Uganda to compare the
effectiveness of AL when administered under supervision
in hospital with fat intake ensured by a meal comprising
~300 mL milk (10 g fat) with 30 g peanuts (13 g fat) ver-
sus AL taken unsupervised at home [6]. In the unsuper-
vised group, only the first dose was taken in the clinic, and
patients were then discharged and advised to take subse-
quent doses with a meal that contained fat (with no fat
content specified), or breast milk in breastfed infants. The
Table 4: Average dietary energy and fat consumption in regions of Africa. [10]




SubSaharan Africa 2220 43
Central Africa 1830 36
East Africa 2040 35
Southern Africa 2080 36
West Africa 2580 57
Table 5: Average dietary fat consumption in sub-Saharan African countries during 2001–2003 [10]















United Republic of Tanzania 31
Zimbabwe 55Page 5 of 7
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tion was 100% in both cohorts (95% CI 98–100 in the
supervised group and 99–100 in the unsupervised group).
The type of meal eaten at home was not recorded, so it
cannot be determined if patients ate especially fatty meals
or standard food. Lumefantrine plasma concentration was
measured on days 3 and 7 in a random selection of 433
patients taking part in the study [31], and multivariate
modelling of these data confirmed that supervised treat-
ment was significantly associated with higher lumefan-
trine concentrations (p < 0.0001) [31]. In another trial,
undertaken in an area of Tanzania with a high level of
resistance to sulfadoxine-pyrimethamine and amodi-
aquine, Mutabingwa and colleagues randomized 1292
children aged 4–59 months with uncomplicated malaria
to AL or to conventional drugs [30]. All agents were taken
at home, without supervision, and no specific advice was
given regarding concomitant food consumption. At 28
days, 97.3% of patients receiving AL showed parasitologi-
cal cure after adjustment for recrudescence.
Together, these findings suggest that food consumption
during unsupervised AL dosing in African patients, includ-
ing children, provides sufficient fat to ensure effective par-
asitological clearance.
As discussed above, the fat consumption of infants shortly
after weaning can be relatively low. It is highly relevant,
therefore, that randomized trials in African children aged
from five months [32,33] or 12 months [34] up to 59
months have consistently shown 28-day PCR-corrected
parasitological cure rates of greater than 95% i.e. similar
to cure rates observed in older populations.
It should be noted that data are scarce concerning lume-
fantrine absorption, and the effect of food consumption,
in patients with HIV/AIDs or other coinfections such as
tuberculosis. Pharmacokinetic and pharmacodynamic
studies are required in the HIV/AIDS population, particu-
larly in the light of increased antimalarial failure rates in
such patients due to increased parasite burden and
reduced host immunity associated with HIV infection (1).
Conclusion
Although lumefantrine bioavailability is enhanced by fat,
pharmacokinetic evidence suggests that only a very small
amount of dietary fat is required [15]. In the event of var-
ying dietary fat intake, such as during unsupervised dos-
ing where fat consumption was not controlled [6] or was
not specifically advised [30], the efficacy of AL does not
appear to have been impaired. This is consistent with pub-
lished statistics concerning the dietary fat intake of African
populations, which indicate that average fat consumption
is generally in the range of 30–60 g/day in subSaharan
African countries. Even in young children shortly after
weaning, in whom fat intake tends to be low, it has been
estimated that fat intake exceeds 10 g/day. In summary,
there is good evidence to suggest that the content of stand-
ard African diets or breast milk is adequate to ensure excel-
lent efficacy for AL.
Abbreviations
ACT: artemisinin-based combination treatment; AL: arte-
mether-lumefantrine; AUC: area under the curve; FAO:
Food and Agriculture Organization; PCR: polymerase
chain reaction.
Competing interests
The authors declare that they have no competing interests
other than COF, who received a research grant from
Novartis in 2002, and NM and ON, who are employees of
Novartis Pharma AG.
Authors' contributions
All authors provided critical review of the text and
approved the final version.
References
1. World Health Organization: Guidelines for treatment of malaria
Geneva: World Health Organization; 2006. 
2. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-
lumefantrine.  Clin Pharmacokinet 1999, 37:105-125.
3. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K,
Hunt P, De Palacios PI: Efficacy and safety of the six-dose regi-
men of arthemeter-lumefrantrine in pediatrics with uncom-
plicated Plasmodium fulciparum malaria: a pooled analysis of
individual patient data.  Am J Trop Med Hyg 2006, 74:991-998.
4. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Pal-
acios PI: Efficacy and safety of artemether-lumefantrine
(Coartem®) tablets (six-dose regimen) in African infants and
children with acute, uncomplicated falciparum malaria.
Trans R Soc Trop Med Hyg 2005, 99:459-467.
5. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B,
Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ: Com-
bination therapy for uncomplicated falciparum malaria in
Ugandan children: a randomized trial.  JAMA 2007,
297:2210-2219.
6. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babi-
gumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W,
Checchi F, Guthmann JP: Supervised versus unsupervised intake
of six-dose artemether-lumefantrine for treatment of acute,
uncomplicated Plasmodium falciparum malaria in Mbarara,
Uganda: a randomized trial.  Lancet 2005, 365:1467-1473.
7. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel
M, Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat
Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M,
Lefèvre G, Ubben D, Premji Z: Efficacy and safety of artemether-
lumefantrine dispersible tablet in African infants and chil-
dren with uncomplicated malaria : a randomised, investiga-
tor-blinded, multi-centre comparison with the crushed
commercial tablet.  Lancet 2008 in press.
8. Wiseman V, Kim M, Mutabingwa TK, Whitty CJ: Cost-effectiveness
study of three antimalarial drug combinations in Tanzania.
PLoS Med 2006, 3:e373.
9. Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Hawela N, Banda P,
Okorosobo T: A cost-effectiveness analysis of artemether
lumefantrine for treatment of uncomplicated malaria in
Zambia.  Malar J 2007, 6:21.
10. Food and Agriculture Organization of the United Nations
Statistics Division   [http://www.fao.org/faostat/foodsecurity/Files/
FoodConsumptionNutrients_en.xls]. Accessed April 2008Page 6 of 7
(page number not for citation purposes)
Malaria Journal 2008, 7:244 http://www.malariajournal.com/content/7/1/244Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
11. Lefèvre G, Thomsen MS: Clinical pharmacokinetics of arte-
mether and lumefantrine (Riamet®).  Clin Drug Invest 1999,
18:467-480.
12. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ: Pharma-
cokinetics and pharmacodynamics of lumefantrine (ben-
flumetol) in acute falciparum malaria.  Antimicrob Agents
Chemother 2000, 44:697-704.
13. Schmidt LE, Dalhoff K: Food-drug interactions.  Drugs 2002,
62:1481-1502.
14. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and
therapeutic response of CGP 56697 (artemether + ben-
flumetol) in malaria patients.  Br J Clin Pharmacol 1998,
46:553-561.
15. Ashley EA, Stepniewska K, Lindegårdh N, Annerberg A, Kham A,
Brockman A, Singhasivanon P, White NJ, Nosten F: How much fat
is necessary to optimize lumefantrine oral bioavailability?
Trop Med Int Health 2007, 12:195-200.
16. Food and Agriculture Organization Corporate Document
Repository. Agriculture, Food and Nutrition for Africa: A
Resource Book for Teachers of Africa. Chapter 7: Food, nutri-
ents and Diets   [http://www.fao.org/docrep/W0078E/
w0078e08.htm#P7404_499006]. Accessed April 2008
17. Food and Agriculture Organization of the United Nations
[http://www.fao.org/]. Accessed April 2008
18. Food and Agriculture Organization of the United Nations.
Food Consumption Food Groups   [http://www.fao.org/faostat/
foodsecurity/Files/FoodConsumptionFoodGroups_en.xls]. Accessed
April 2008
19. Food and Agriculture Organization of the United Nations/
US Department of Health, Education and Welfare  Food Com-
position Table for Use in Africa  [http://www.fao.org/docrep/003/
X6877E/X6877E00.htm#]. Accessed April 2008
20. Prentice A, Prentice AM, Whitehead RG: Breast-milk fat concen-
trations of rural African women. 2. Long-term variations
within a community.  Br J Nutr 1981, 45:495-503.
21. Kent JC, Mitoulas LR, Cregan MD, Ramsay DT, Doherty DA, Hart-
mann PE: Volume and frequency of breastfeedings and fat
content of breast milk throughout the day.  Pediatrics 2006,
117:e387-395.
22. Larnkjaer A, Schack-Nielsen L, Michaelsen KF: Fat content in
human milk according to duration of lactation.  Pediatrics 2006,
117:988-989.
23. Liyanage C, Hettiarachchi M, Mangalajeewa P, Malawipathirana S:
Adequacy of vitamin A and fat in the breast milk of lactating
women in south Sri Lanka.  Public Health Nutr 2008 in press.
24. Prentice AM, Paul AA: Fat and energy needs of children in
developing countries.  Am J Clin Nutr 2000, 72(5
Suppl):1253S-1265S.
25. Hudson GJ, John PMV, Paul AA: Variation in the composition of
Gambian foods; the importance of water in relation to
energy and protein content.  Ecol Food Nutr 1980, 10:9-17.
26. Onyango AW, Receveur O, Esrey SA: The contribution of breast
milk to toddler diets in western Kenya.  Bull World Health Organ
2002, 80:292-299.
27. von Seidlein L, Jaffar S, Pinder M, Haywood M, Snounou G, Gemperli
B, Gathmann I, Royce C, Greenwood B: Treatment of African
children with uncomplicated falciparum.  J Infect Dis 1997,
176:1113-1116.
28. von Seidlein L, Bojang K, Jones P, Jaffar S, Pinder M, Obaro S, Doherty
T, Haywood M, Snounou G, Gemperli B, Gathmann I, Royce C,
McAdam K, Greenwood B: A randomized controlled trial of
artemether/benflumetol, a new anti-malarial and pyrimeth-
amine/sulfadoxine in the treatment of uncomplicated falci-
parum malaria in African children.  Am J Trop Med Hyg 1998,
58:638-644.
29. Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P,
Beck HP, Tanner M, Royce C: Efficacy and safety of CGP 56697
(artemether and benflumetol) compared with chloroquine
to treat acute falciparum malaria in Tanzanian children aged
1–5 years.  Trop Med Int Health 1998, 3:498-504.
30. Mutabingwa T, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C,
Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine +
sulfadoxine-pyrimethamine, amodiaquine +artesunate, and
artemether-lumefantrine for outpatient treatment of
malaria in Tanzanian children: a four-arm randomised effec-
tiveness trial.  Lancet 2005, 365:1474-1480.
31. Checchi F, Piola P, Fogg P, Bajunirwe F, Biraro S, Grandesso F, Ruza-
gira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Tay-
lor WR: Supervised versus unsupervised antimalarial
treatment with six-dose artemether-lumefantrine: pharma-
cokinetics and dosage-related findings from a clinical trial in
Uganda.  Malaria J 2006, 5:59.
32. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla
S: Efficacy and safety of artemisinin-based antimalarial in the
treatment of uncomplicated malaria in children in southern
Tanzania.  Malar J 2007, 6:146.
33. Koram KA, Abuaku B, Duah N, Quashie N: Comparative efficacy
of antimalarial drugs including ACTs in the treatment of
uncomplicated malaria among children under 5 years in
Ghana.  Acta Trop 2005, 95:194-203.
34. Fanello CI, Karema C, van Doren W, Van Overmeir C, Ngamije D,
D'Alessandro U: A randomised trial to assess the safety and
efficacy of artemether-lumefantrine (Coartem) for the
treatment of uncomplicated Plasmodium falciparum malaria
in Randa.  Trans R Soc Trop Med Hyg 2007, 101:344-350.Page 7 of 7
(page number not for citation purposes)
